Výsledky vyhledávání

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Autor: Eliot A. Brinton, Uma Kher, Sukrut Shah, Christopher P. Cannon, Michael Davidson, Antonio M. Gotto, Tanya B. Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter, M. Gerstman, L. Howes, K. Kostner, P. Nestel, D. Sullivan, H. Brath, J. Patsch, B. Paulweber, H. Toplak, C.M. Constance, E. Howlett, D. Mymin, L. Pliamm, K.K. Saunders, J.-C. Tardif, R. Tytus, P. Aschner, S. Keinänen-Klukaanniemi, T. Strandberg, M.-R. Taskinen, G. Luc, D. Richter, J.L. Schlienger, Y. Zaïr, K.-F. Appel, M. Baar, C. Luley, U. Overhoff, T. Pomykaj, T. Schaefer, S.T. Lau, K.L.F. Lee, K. Tan, B. Tomlinson, M.W. Tsang, K. Badacsonyi, Á. Kalina, N. Kanakaridisz, L. Márk, É. Péterfai, L. Regos, I. Reiber, J. Takács, A. Vértes, A. Elis, D. Gavish, D. Harats, O. Hussein, T. Hayek, E. Leitersdorf, A.K. Bin Abdul Ghapar, K.H. Chee, S.B. Ismail, K.H. Ling, G.R.L. Ramanathan, K.H. Sim, R. Alvarado, M. Benavides, G.E. Cardona, G. Gonzalez, J. Verdejo, D.C.G. Basart, B.P.M. Imholz, J.J.C. Jonker, P.R. Nierop, J.L. Posma, Th.B. Twickler, E. Barrington-Ward, R. Cutfield, D.H. Friedlander, R.S. Scott, H. Istad, G. Langslet, G.K. Skjelvan, S.J. Campodónico Hoyos, R. Coloma Araniya, A. Gallegos C., C.A. Pino Morales, L. Watanabe, G.P. Arutyunov, A.B. Blokhin, M.G. Bubnova, S.Y. Marcevich, C. Álvarez Sánchez, L.A. Álvarez-Sala Walther, B. Gil Extremera, F. Perez Jimenez, L. de Teresa Parreño, C.-P. Anderberg, U. Hedin, A. Hellberg, P. Höök, T. Kjellström, P. Nilsson, A.G. Olsson, U. Rosenqvist, K. Tolagen, T. Wolff, A. Baskin, H.E. Bays, R.I. Bernstein, N. Bittar, E.A. Brinton, L.H.K. Chee, R.A. Cottiero, R.D. D'Agostino, M.H. Davidson, P.S. Denker, R.K. Garcia, R.K. Hippert, T. Isakov, S.R. Kaster, B. Kerzner, E.J. Klein, M.J. Koren, M.E. Kutner, D. Liljenquist, D.G. Lorch, R. Lorraine, B.C. Lubin, N.M. Lunde, T.J. Majchrzak, J.M. McKenney, S. Mukherjee, D.D. Muse, M.S. Otruba, J.E. Pappas, K. Patrick, S.J. Powell, E. Riffer, L.D. Rink, J.L. Rohlf, J.B. Rosen, P.D. Rosenbilt, E.M. Roth, C.J. Rubenstein, J. Rubino, L.A. Rudolph, A. Schneider, W.G. Short, J.C. Silverfield, D.P. Suresh, G.A. Tarshis, P.D. Toth, R.W. Townsend, T.O. Wahl

Publikováno v: Journal of clinical lipidology

Background In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib (DEFINE) trial, anacetrapib added to statin produced robust low-density lipoprotein cholesterol (LDL-C)-lowering and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0c778769d9b9d7a78e7c69d7f43bd3
https://pubmed.ncbi.nlm.nih.gov/25670362

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study)

Autor: F, Garmendia, A S, Brown, I, Reiber, P C, Adams

Publikováno v: Current medical research and opinion. 16(3)

The effectiveness and safety of simvastatin in reducing low-density lipoprotein cholesterol (LDL-C) to target levels in patients with coronary heart disease (CHD) were evaluated in the GOALLS (Getting to Appropriate LDL-C Levels with Simvastatin) stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8d895160d301c8b96aec3d4e6754f175
https://pubmed.ncbi.nlm.nih.gov/11191011

Zobrazit plný text záznamu

[Incidence of familial defective apolipoprotein B-100 in cases of patients diagnosed with familial hypercholesterolemia]

Autor: A, Kalina, E, Czeizel, L, Romics, G, Pados, I, Reiber, A, Dósa, I, Hermányi, Z, Lakatos, J, Tarján, E, Kollega-Tarsoly, M, Kovács, C, Szalai, A, Császár

Publikováno v: Orvosi hetilap. 139(13)

Familial Hypercholesterolemia (FH) and Familial Defective Apolipoprotein B-100 (FDB) are monogenic, autosome, dominantly inherited diseases appearing as type II/a primary hypercholesterolemia. The frequency of the heterozygositic forms is 1:700-1:500

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3e3c22ec76ff34eae54a831f7740b357
https://pubmed.ncbi.nlm.nih.gov/9578704

Zobrazit plný text záznamu

[Reducing low density lipoprotein-cholesterol levels by apheresis]

Autor: I, Reiber, A, Gógl

Publikováno v: Orvosi hetilap. 135(11)

The predominate number of homozygote familial hypercholesterolemic and approximately 20% of heterozygotes are resistant to low cholesterol diet and lipid lowering pharmacological treatment even in combination of 2 or more drugs. In such cases, the se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e5925427b9e4c1a72fb86b5aa7454e4a
https://pubmed.ncbi.nlm.nih.gov/8159408

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání